Linden Thomas Advisory Services LLC Purchases 169 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Linden Thomas Advisory Services LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,436 shares of the company’s stock after acquiring an additional 169 shares during the period. Linden Thomas Advisory Services LLC’s holdings in IDEXX Laboratories were worth $3,074,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.7 %

NASDAQ:IDXX opened at $435.33 on Friday. The company has a 50-day moving average price of $423.74 and a 200-day moving average price of $456.35. The stock has a market cap of $35.65 billion, a price-to-earnings ratio of 41.98, a P/E/G ratio of 3.63 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. During the same period last year, the business posted $2.53 earnings per share. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. Equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Barclays dropped their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Piper Sandler restated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.